Spots Global Cancer Trial Database for Trial of Endocrine Against Locoregional Therapy First in Postmenopausal Women With Early Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Trial of Endocrine Against Locoregional Therapy First in Postmenopausal Women With Early Breast Cancer
Official Title: Randomized Trial of Endocrine Therapy Against Locoregional Therapy First. A DBCG Trial in Postmenopausal Patients With Operable Hormone Receptor Positive Tumors Larger Than 2 cm.
Study ID: NCT00908531
Conditions
Interventions
Study Description
Brief Summary: The hypothesis to be addressed in this randomized phase III trial is that 4 months of letrozole may be superior to surgery as primary therapy for early stage hormone receptor positive breast cancer in postmenopausal women, provided that these patients will receive definitive and radical surgery and adjuvant therapies as otherwise indicated at the completion of preoperative letrozole.
Detailed Description:
Eligibility
Minimum Age: 60 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Dept. of Breast Surgery; Aalborg Sygehus, Aalborg, , Denmark
Dept. of Breast Surgery; Rigshospitalet, Copenhagen, , Denmark
Dept. of Surgery; Sydvestjysk Sygehus Esbjerg, Esbjerg, , Denmark
Dept. of Breast Surgery; Herlev Hospital, Herlev, , Denmark
Dept. of Oncology; Odense University Hospital, Odense, , Denmark
Depart. of Breast Surgery, Ringsted Sygehus, Ringsted, , Denmark
Dept. of Breast Surgery; Vejle Sygehus, Vejle, , Denmark
Dept. of Breast Surgery; Regionshospitalet Viborg, Viborg, , Denmark
Dept. of Surgery; Århus Sygehus, Århus, , Denmark
Contact Details
Name: Bent Ejlertsen, MD, PhD
Affiliation: DBCG
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
